Lineage Q2 2023 Earnings Report
Key Takeaways
Lineage Cell Therapeutics reported a net loss of $5.2 million, or $0.03 per share, for the second quarter ended June 30, 2023. Total revenues were $3.2 million, and total operating expenses were $8.1 million. Cash, cash equivalents, and marketable securities totaled $45.9 million as of June 30, 2023.
Lineage continued to execute across multiple fronts, advancing clinical and preclinical cell transplant programs and supporting alliances.
The company focused on its partnership with Roche and Genentech and continued support for the Phase 2a clinical study of OpRegen.
Lineage reported positive clinical results from a Phase 1 study of VAC2 in non-small cell lung cancer with Cancer Research UK.
The company is focused on making progress across its pipeline while maintaining a commitment to disciplined spending.
Lineage
Lineage
Forward Guidance
Lineage expects its cash, cash equivalents, and marketable securities to support planned operations into Q4 2024.